Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | GLS | O94925 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6355642 | 1.00 | NR1H2 (0.44) | NR1H2ATMTSHRALOX15ESR2 | |
| SCHEMBL1219800 | 0.90 | ADORA1 (0.43) | ATMTSHRALOX15ESR2GLS | |
| SCHEMBL21047249 | 0.90 | ADORA1 (0.43) | ATMTSHRALOX15ESR2GLS | |
| SCHEMBL1219803 | 0.90 | ADORA1 (0.43) | ATMTSHRALOX15ESR2GLS | |
| SCHEMBL21104807 | 0.88 | ATM (0.42) | NR1H2ATMTSHRALOX15ESR2 | |
| SCHEMBL16789937 | 0.82 | ATM (0.45) | NR1H2ATMTSHRALOX15ESR2 | |
| SCHEMBL929117 | 0.82 | ADORA1 (0.43) | ATMTSHRALOX15ESR2GPR119 | |
| SCHEMBL929119 | 0.82 | ADORA1 (0.43) | ATMTSHRALOX15ESR2GPR119 | |
| SCHEMBL654580 | 0.82 | ADORA1 (0.43) | ATMTSHRALOX15ESR2GPR119 | |
| SCHEMBL25635587 | 0.81 | HDAC1 (0.41) | NR1H2ATMTSHRALOX15MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595327-B2 | Exo-N-Hydroxy-3-[methyl({4-[(2-methylquinolin-4-yl) methoxy]phenyl}sulfonyl)amino]bicyclo[2.2.1]heptane-2-carboxamide; rheumatoid arthritis (RA), juvenile RA, psoriatic arthritis, ankylosing spondylitis, psoriasis, osteoarthritis, tumor metastasis, sepsis, AIDS, ulcerative colitis, multiple sclerosis | WYETH (US) | 2009-09-29 | — | — | US | disclosed |
| US-20060211730-A1 | Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase | WYETH (US) | 2006-09-21 | — | — | US | disclosed |
| US-6949546-B2 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-09-27 | — | — | US | disclosed |
| US-20040058961-A1 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | KO SOO S (US) | 2004-03-25 | — | — | US | disclosed |
| US-6627629-B2 | Useful for the treatment or prevention of asthma and other allergic diseases. | BRISTOL-MYERS SQUIBB PHARMA | 2003-09-30 | — | — | US | disclosed |
| CN-1440402-A | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-09-03 | — | — | CN | disclosed |
| US-20030032654-A1 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211730-A1 | Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase | SI, MMP12, TNF | NR1H2 399/4885ATM 1232/4885TSHR 768/4885 |
| US-20040058961-A1 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | CCR3, CCR1, ACKR3 | NR1H2 149/4885ATM 4768/4885TSHR 2053/4885 |
| US-20030032654-A1 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | CCR3, CCR1, ACKR3 | NR1H2 149/4885ATM 4768/4885TSHR 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.